Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet by Jamieson, P. M. et al.
ARTICLE
Urocortin 3 transgenic mice exhibit a metabolically favourable
phenotype resisting obesity and hyperglycaemia
on a high-fat diet
P. M. Jamieson & M. E. Cleasby & Y. Kuperman & N. M. Morton & P. A. T. Kelly &
D. G. Brownstein & K. J. Mustard & J. M. Vaughan & R. N. Carter & C. N. Hahn &
D. G. Hardie & J. R. Seckl & A. Chen & W. W. Vale
Received: 15 March 2011 /Accepted: 26 April 2011 /Published online: 11 June 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis Urocortins are the endogenous ligands for
the corticotropin-releasing factor receptor type 2 (CRFR2),
which is implicated in regulating energy balance and/or
glucose metabolism. We determined the effects of chronic
CRFR2 activation on metabolism in vivo, by generating and
phenotyping transgenic mice overproducing the specific
CRFR2 ligand urocortin 3.
Methods Body composition, glucose metabolism, insulin
sensitivity, energy efficiency and expression of key meta-
bolic genes were assessed in adult male urocortin 3
transgenic mice (Ucn3
+) under control conditions and
following an obesogenic high-fat diet (HFD) challenge.
Results Ucn3
+ mice had increased skeletal muscle mass
with myocyte hypertrophy. Accelerated peripheral glucose
disposal, increased respiratory exchange ratio and hypo-
glycaemia on fasting demonstrated increased carbohydrate
metabolism. Insulin tolerance and indices of insulin-
stimulatedsignallingwereunchanged,indicatingthese effects
werenot mediatedbyincreasedinsulinsensitivity.Expression
of the transgene in Crfr2 (also known as Crhr2)-null mice
negated key aspects of the Ucn3
+ phenotype. Ucn3
+ mice
were protected from the HFD-induced hyperglycaemia and
increased adiposity seen in control mice despite consuming
more energy. Expression of uncoupling proteins 2 and 3 was
higher in Ucn3
+ muscle, suggesting increased catabolic
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muscle, providing a potential paracrine mechanism in which
urocortin 3 acts upon CRFR2 to link the altered metabolism
and muscular hypertrophy observed.
Conclusions/interpretation Urocortin 3 acting on CRFR2
in skeletal muscle of Ucn3
+ mice results in a novel
metabolically favourable phenotype, with lean body com-
position and protection against diet-induced obesity and
hyperglycaemia. Urocortins and CRFR2 may be of interest
as potential therapeutic targets for obesity.
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Abbreviations
AMPK AMP-activated protein kinase
CRFR2 Corticotropin-releasing factor receptor type 2
GTT Glucose tolerance test
HFD High-fat diet
ITT Insulin tolerance test
LFD Low-fat diet
mTOR Mechanistic target of rapamycin
p70S6 p70 S6 kinase
PAS Periodic acid–Schiff’s reagent
PEPCK Phosphoenolpyruvate carboxykinase 1
RER Respiratory exchange ratio
Ucn3
+ Urocortin 3 transgenic mice
UCP Uncoupling protein
 VCO2 Rate of carbon dioxide production
 VO2 Rate of oxygen uptake
Introduction
Urocortins are the endogenous ligands for the corticotropin-
releasing factor receptor type 2 (CRFR2) [1–5]. Together
with corticotropin-releasing factor, urocortins are important
regulators of neurohormonal responses to stress [6],
integrating adaptive changes in energy flux, and glucose
and lipid metabolism [7]. However, chronic stress has been
linked to an increased risk of the metabolic syndrome and
its components (type 2 diabetes mellitus, dyslipidaemia,
hypertension, obesity, atherosclerotic heart disease) [8].
Significant roles for CRFR2/urocortins in regulating
metabolism have indeed been identified. Crfr2 (also known
as Crhr2)-null mice resist high-fat diet (HFD)-induced
obesity and insulin resistance, effects thought to be
primarily centrally mediated, with increased sympathetic
activity increasing thermogenesis in brown adipose tissue
and hence the metabolic rate [9, 10]. Intriguingly, however,
urocortins are also present at high levels in peripheral
metabolic tissues, including skeletal muscle [11, 12],
implying that these ‘stress regulators’ have local peripheral
as well as central metabolic actions.
In vitro, skeletal muscle CRFR2 stimulates futile
substrate cycling between de novo lipogenesis and lipid
oxidation, with a requirement for glucose metabolism and
AMP-activated protein kinase (AMPK) signalling [13].
This has spawned suggestions that CRFR2 agonists may
protect muscle from excessive intracellular lipid storage and
thus from lipotoxicity-induced insulin resistance. However,
Ucn2-null mice are protected against diet-induced obesity,
with increased insulin sensitivity in skeletal muscle,
perhaps due to absence of paracrine antagonism of insulin
by urocortin 2 [11]. Ucn3-null mice are also protected from
glucose intolerance [14], yet pancreatic urocortin 3 leads to
enhanced beta cell insulin production [12]. Thus, although
urocortinsareclearlypotentregulatorsofglucosemetabolism,
underlying mechanisms and key tissue(s) of action are
various, and the predominant effects unclear.
The necessary pharmacological studies of urocortin
administration in vivo have to date only involved short-
termtreatmentsduetoexperimentalconstraints.Urocortin3is
the most specific ligand known for CRFR2 [4, 5]. To model
the effects of chronic pharmacological CRFR2 activation
on metabolism in vivo, we exploited this specificity, and
generated and phenotyped a transgenic mouse over-
expressing Ucn3.
Methods
Production of transgenic mice The Ucn3 transgene
(Ucn3
+) was constructed by ligating the mouse Ucn3 open
reading frame [4] into the EcoRI restriction site of the
pBROAD3 vector (InvivoGen, San Diego, CA, USA)
(Fig. 1a), placing it downstream of the mouse Rosa26 (also
known as Gt(ROSA)26Sor) promoter and upstream of a
human β-globin polyA signal. The expression cassette was
injected into the pronucleus offertilised (C57BL/6×BALB/c)
F1 mouse oocytes. Mice were genotyped by PCR of genomic
DNA. Mouse Ucn3-specific sense (5′-ATGACAAC
CAAACGCACCTCCAGA-3′) and human ß-globin-specific
antisense (5′-GGCCCTTCATAATATCCCCCAGTT-3′)
primers resulted in a 450 bp transgene-specific amplification
product. Five founder animals were identified. Transgene
expression was quantified in F3 generations. The line with
highest expression was used for subsequent analyses. Crfr2-
null mice [15] were crossed with Ucn3
+ mice for two
generations to generate homozygous Crfr2-null mice carry-
ing the Ucn3
+ transgene for some experiments.
Animal husbandry Mice were housed in temperature- and
lighting-controlled rooms (lights on for 12 h) with free
access to laboratory chow and water except where stated.
Diabetologia (2011) 54:2392–2403 2393Experiments were carried out on male mice between 16 and
26 weeks old. Ucn3
+ mice were heterozygous for the
transgene and controls were transgene-negative littermates.
Principles of laboratory animal care (NIH No. 85-23, 1985)
were followed. All procedures were approved by The Salk
Institute Animal Use and Care Committee or carried out
according to the UK Animals Scientific Procedures Act,
1986. Food intake was measured over 6 days in individu-
ally housed mice and the average intake per day was
adjusted for body weight as per Kleiber’s allometric law.
In vivo studies Procedures were carried out in the
morning. ‘Fed’ is defined as food not withheld, ‘fasted’
is defined as 18 h food deprivation. Measurements were
carried out fed except where stated, with the exception of
glucose tolerance tests (GTTs) and insulin tolerance tests
(ITTs), which were carried out following 6 or 3 h food
deprivation, respectively. Glucose (2 g/kg) or insulin
(0.75 IU/kg) was administered i.p. in saline and tail
blood collected for immediate glucose measurement
(Lifescan OneTouch Ultra glucometer; Johnson & John-
son, Milpitas, CA, USA). For insulin measurements,
blood was collected by retro-orbital bleed. For other
measurements, blood and tissues were collected immedi-
ately after animals had been killed. For glucagon
response test and insulin signalling studies, see Electronic
supplementary material (ESM), Methods.
High-fat feeding Mice were fed an HFD (45% energy as
fat) or control low-fat diet (LFD) (10% energy as fat)
(products D12451 and D12450B, respectively; Research
Diets, New Brunswick, NJ, USA) from weaning (3 weeks)
until 16 weeks old and weighed weekly. Food intake was
quantified at 15 weeks. GTT, ITT and time course
measurement of blood glucose levels during fasting were
performed, and pre- and post-fasting weight recorded. Mice
were culled fasted or fed, and individual fat depots and
hindlimb muscles were dissected out and weighed.
Fig. 1 Ucn3 overexpression in tissues of Ucn3
+ transgenic mice
results in increased skeletal muscle mass with myocyte hypertrophy.
a A construct for overexpression of Ucn3 was designed as shown,
putting the transgene under the control of the mouse Rosa26 promoter.
The position of primers used to genotype mice is shown. b Northern
blots of RNA extracted from tissues of Ucn3
+ mice and control
littermates probed with Ucn3 and S16 cDNA. B, brain; H, heart; L,
liver; K, kidney; M, muscle. c Growth curves of Ucn3
+ mice (black
squares) show they are heavier than controls (white squares) from
6 weeks of age (n=17–19). Whole body composition analysis showed
this to be due to (d) increased lean tissue mass with (e) no change in
fat mass (n=10). f Weight of individual skeletal muscles showing that
Ucn3
+ mice have increased skeletal muscle mass (n=13–17).
g Muscle histology (×200 magnification, scale bar 50 μm) and (h)
myocyte cross-sectional area reveal increased muscle mass to be due
to myocyte hypertrophy (n=4). i Muscle fibre type distribution in the
soleus muscle. Extensor digitorum longus and gastrocnemius muscles
were >98% type 2 in control and Ucn3
+ mice (not shown). *p<0.05
vs control. d–i Black bars, Ucn3
+; white bars, control
2394 Diabetologia (2011) 54:2392–2403Metabolism cage studies Rates of oxygen uptake (  VO2),
rates of carbon dioxide production (  VCO2), food intake
and locomotor activity (ESM Methods)w e r em e a s u r e d
continuously and simultaneously over 3 days (LabMaster;
TSE-Systems, Bad Homburg, Germany) after 48 h adap-
tation in singly housed mice.
Body composition analysis Body composition of whole
carcasses was determined using PIXImus densitometry
(GE-Lunar, Madison, WI, USA) as previously validated
[16].
Histology Liver and quadriceps muscles were formalin-
fixed, dehydrated in graded ethanol/xylene, paraffin-
embedded, sectioned at 5 mm intervals and stained with
haematoxylin and eosin. Liver was stained with periodic
acid–Schiff's reagent (PAS) with and without diastase
pre-treatment. For measurement of myocyte size, hind-
quarters were skinned and fixed, and decalcified in 10%
(wt/vol.) formaldehyde, 8% (wt/vol.) formic acid and 1%
(vol./vol.) methanol with the legs in mild flexion for 48 h.
Transverse sections through the mid-femur were paraffin-
embedded, sectioned at 4 mm intervals and stained with
PAS. Areas of 20 myocytes/mouse were measured from
×300 digital images of rectus femoris muscle in cross-
section using imaging software (QCapture Pro; QImaging,
Surrey, BC, Canada).
Muscle fibre typing Tissues were dissected and snap-frozen
in liquid nitrogen-cooled melting isopentane. Transverse
sections (8 μm) were stained with myosin ATPase to
demonstrate fibre types classified as type 1 or type 2 as
previously described [17]. Digital images (100×) covering
the whole section and including, when possible, a minimum
of 350 fibres, were analysed toquantify fibre type distribution
usingImage-ProPlussoftware(MediaCybernetics,Bethesda,
MD, USA).
Hormone measurements Insulin and IGF-1 were measured
using Sensitive Rat Insulin RIA (Linco Research, St
Charles, MO, USA) and Mouse/Rat IGF-1 Quantikine
ELISA (R&D Systems, Minneapolis, MN USA) kits,
respectively. For corticosterone, glucagon and growth
hormone measurements, see ESM Methods.
Combined GTT and [
3H]glucose or 2-deoxy[
3H]glucose
tracer uptake into tissues This was carried out based on
methods previously described [18, 19]. Mice were fasted
for 3 h and weighed. After tracer (3.7 MBq/mlD-[3-
3H]
glucose or 1.9 MBq/ml 2-deoxy-D-[2,6-
3H]glucose solution
[Amersham Pharmacia Biotech, Little Chalfont, UK]) with
2 g/kg glucose in 0.3 ml saline had been injected, blood
glucose and plasma radioactivity were measured over
90 min and AUC calculated. At 90 min, mice were killed,
and tissues dissected and snap-frozen. To estimate glucose
uptake, tissues were homogenised in distilled H2O and
centrifuged for 10 min at 600 g and 4°C. Total [
3H]glucose
and [
3H]glucose 6-phosphate were counted in the superna-
tant fraction after separation using a 100 to 200 mesh anion
exchange resin column (AG1-X8; Bio-Rad, Hercules, CA,
USA). Blood radioactivity AUC and [
3H]glucose uptake
were used to calculate glucose clearance into each tissue.
Total tissue glycogen was estimated as previously described
[20]. For glucose incorporation into glycogen, radioactivity
of digested samples was divided by the specific activity in
serum over the GTT time course. For 2-deoxyglucose
uptake, weighed tissues were digested at 50°C overnight in
1 ml Soluene-350 (Packard Bioscience, Groningen, the
Netherlands). Uptake was calculated from the plasma
profiles of 2-deoxy[
3H]glucose and glucose, together with
concentrations of radiolabelled tracer in tissue.
Hyperinsulinaemic clamps Mice were implanted with an
indwelling jugular catheter 3 days prior to experiments.
Fastedmicereceiveda2hbasalsalineinfusion,thena primed
continuous infusion of short-acting insulin consisting of a
bolus of 100 mU/kg for 3 min, followed by a constant rate of
2.5 mU kg
−1 min
−1 (a standard protocol designed to achieve
a high physiological insulin level of ~450 pmol/l [21]).
Glucose (20% wt/vol. in saline) was infused at a variable
rate (2.5–12 μl/min) to maintain euglycaemia (6–7m m o l / l )
as far as possible. Tail blood samples were used to monitor
glycaemia at baseline (0), and at 20, 40, 60, 70, 80, 90, 100,
110 and 120 min.
Phosphoenolpyruvate carboxykinase 1 activity This was
assayed in liver homogenates as previously described [22].
Northern blotting Total RNA was extracted from tissues
and northern blotting carried out as previously described
[23] using deoxycytidine 5′-[
32P]triphosphate-labelled
mouse Ucn3 cDNA. Blots were rehybridised with S16
probes to control for loading.
Tissue lysates, SDS-PAGE and immunoblotting Protein
abundance and phosphorylation in tissue lysates was
quantified by SDS-PAGE as previously described [19].
Primary antibodies were from Cell Signaling Technology
(Beverley, MA, USA), except pY612-IRS-1 (BioSource
International, Camarillo, CA, USA), total IRS-1 (Upstate
Cell Signaling Solutions, Waltham, MA, USA), myostatin
(Millipore, Watford, UK) and tubulin (Li-COR Biosciences,
Lincoln, NE, USA). Primary antibodies against phosphor-
ylated proteins were used at 1:500 dilution, those against
tubulin at 1:10,000 and all other primary antibodies at
1:1,000. For AMPK, see ESM methods.
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tissues and 500 ng reverse-transcribed to cDNA using a kit
(QuantiTect DNase; Qiagen, Crawley, UK). PCR cycling
was carried out using a LightCycler480 (Roche Diagnostics,
Mannheim, Germany). Standard curves were constructed for
each assay using serial dilution of cDNA pooled from all
samples. Reactions were performed in triplicate. Results were
corrected for 18S, cyclophilin A and Hprt1 (also known as
Hprt) mRNA expression levels, which were not different
between groups. For cyclophilin A, Ppargc1a, Ucn2 and
Ucn3, assays Mn02342429-g1, Mm00440939-m1,
Mm01227928-s1 and Mm00453206-s1 (Applied Biosystems,
Carlsbad, CA, USA) were employed. Other gene-specific
assays and probes were designed using the Universal
ProbeLibrary Assay Design Center (Roche). Polymerase,
buffer and dNTPs were provided from the LightCycler480
Probes Master kit (Roche). Details of primer sequences and
probes are available upon request.
Statistical analysis Statistical analyses employed the
Student’st w o - t a i l e dt test, or one- or two-way ANOVA
with post hoc analysis using Bonferroni’so rD u n n e t t ’st e s t
asappropriate.Dataarepresentedasmean±SEM.Differences
wereconsideredstatisticallysignificantatp<0.05.Forfurther
details, see ESM, Methods.
Results
Generation of transgenic mice overexpressing Ucn3 Ucn3
+
mice were generated by placing the coding region of
mouse Ucn3 under the control of the ubiquitously
expressed Rosa26 promoter (Fig. 1a). Progeny from
founders were screened and a line selected that expressed
Ucn3 mRNA at high levels in a wide range of organs, as
reflected in elevated plasma and tissue peptide levels
(Fig. 1ba n dT a b l e1). Mice carrying the transgene were
born at the expected Mendelian ratio and showed no
obvious signs of ill health until at least 18 months old or
any significant pathology on routine post-mortem exami-
nation (not shown).
Ucn3
+ mice have increased skeletal muscle mass Ucn3
+
mice were heavier than wild-type littermates by 6 weeks
old. By 12 weeks this difference stabilised with Ucn3
+
mice weighing ~12% more than controls (Fig. 1c). Carcass
analysis revealed that this was entirely due to increased lean
tissue mass (Fig. 1d, e). Weights of parenchymal organs,
femoral length and nose to tail length were not significantly
different between genotypes (not shown). Individual skeletal
muscle weights (whether predominantly type 1, type 2 or
mixed fibre type) were greater in Ucn3
+ mice (Fig. 1f),
whereas fat pad weights were unaltered (ESM Fig. 1).
Histology revealed muscle hypertrophy with increased
myofibre diameter (Fig. 1g, h), and a shift towards type 2
glycolytic muscle fibre type (Fig. 1i).
Ucn3
+ mice have an increased energy requirement Food
intake was significantly greater in Ucn3
+ mice, even when
adjusted for body weight, signifying an increased energy
requirement (Fig. 2a).  VO2 and  VCO2 were ~7% higher in
Ucn3
+ mice (Fig. 2b, c), but individual variation did not
allow conclusions to be drawn on the significance of this.
Increased respiratory exchange ratio (RER) indicated higher
proportional use of carbohydrate as a metabolic fuel source
(Fig. 2d). While voluntary running wheel activity was not
different, Ucn3
+ mice showed increased spontaneous
activity in metabolism cages (ESM Fig. 1). This may in
part account for their increased energy requirements, but
cannot explain other aspects of their phenotype including
glucose metabolism as described below.
Ucn3
+ mice show more rapid falls in blood glucose during
fasting and a GTT Ucn3
+ mice had lower fed blood
glucose levels, a more rapid drop in glucose at the onset
of fasting and significantly lower glucose levels during
fasting (Fig. 2e). Ucn3
+ mice showed improved glucose
tolerance across a GTT (Fig. 2f). To determine whether the
effects of Ucn3
+ were mediated, as anticipated, by CRFR2,
Ucn3
+ mice were crossed with Crfr2-null mice. Impor-
tantly, the body mass increase, and fasting and GTT
glucose-lowering effects of the Ucn3
+ transgene were
negated by the Crfr2-null mutation, confirming that muscle
hypertrophy and glucose phenotype were dependent on
CRFR2 (Fig. 2g–i). Ucn3
+ mice had increased uptake of 2-
deoxy[
3H]glucose to tissues per unit mass, particularly
skeletal muscle, during a GTT (Fig. 2j), demonstrating that
their accelerated disposal of a glucose load was not due to
increased muscle mass alone. Ucn3
+ muscle showed
increased glycogen storage and incorporation of [
3H]
glucose into glycogen during the GTT (Fig. 2k, l).
Table 1 Urocortin 3-like immunoreactivity in tissues of control and
Ucn3
+ mice
Tissue Control (pg/g) Ucn3
+ (pg/g)
Brain 257±29 11,308±475
Heart ND 597±54
Liver 105±12 576±38
Pancreas 550±135 1,627±231
Plasma 52±5 171±21
Data are mean±SEM, n=3
ND, not detectable
2396 Diabetologia (2011) 54:2392–2403Decreased phosphorylation of glycogen synthase at residue
S641 indicated increased glycogen synthase activity
(Fig. 2m).
Ucn3
+ mice exhibit adequate counter-regulatory responses
upon fasting Since lower blood glucose levels were
consistently found in fed and fasted Ucn3
+ mice (Fig. 2e),
we examined their counter-regulatory responses. Following
fasting, circulating corticosterone and glucagon levels in
Ucn3
+ mice, as well as glucose production in response to
glucagon administration to fed mice, were the same as in
controls (ESM Fig. 2). Moreover, in Ucn3
+ mice, fasting
insulin was lower than in controls, showing appropriate
downregulation in response to hypoglycaemia (Fig. 3a).
Ucn3
+ mice lost a greater proportion of liver weight
(a measure of glycogen mobilisation and depletion) and
showedlesshepaticglycogenstainingafterfasting(Fig.3b, c).
Pepck (also known as Pck1)m R N Ae x p r e s s i o nw a s
upregulated appropriately in Ucn3
+ mice after fasting
(Fig. 3d) and phosphoenolpyruvate carboxykinase 1
(PEPCK) enzyme activity levels were increased when fed
and fasted, consistent with gluconeogenesis being active at all
times (Fig. 3e).
Ucn3
+ mice have normal insulin sensitivity Lower fasting
insulin/glucose ratio indicated the possibility of increased
insulin sensitivity in Ucn3
+ mice (Fig. 4a). However,
during an ITT there was no difference in the magnitude of
response to insulin, implying no difference in insulin
sensitivity (Fig. 4b). Moreover, basal (fed) activating
phosphorylation of the key signalling intermediates, Akt
and IRS-1, in skeletal muscle and liver was decreased in
Ucn3
+ mice, presumably due to their lower insulin levels
(Fig. 4c). While exogenous insulin caused the expected
increase in IRS-1 and Akt phosphorylation, there were no
differences between genotypes (ESM Fig. 2), again
Fig. 2 Ucn3
+ mice have an
increased energy requirement
and uptake of glucose to tissues.
a Food intake is higher in
Ucn3
+ mice (black bars) than
controls (white bars)
(n=10–11). b  VCO2,( c)  VO2
and (d) RER are elevated
in Ucn3
+ mice (n=5–7).
e Blood glucose levels during
fasting (n=10–12) and (f) dur-
ing GTT (n=10) showed lower
glucose in Ucn3
+ mice (black
squares) than in controls (white
squares). g Body weight, (h)
fasting blood glucose and
(i) GTT in Ucn3
+ mice on a
Crfr2-null background (n=5–6)
show that these aspects of
phenotype are mediated via
CRFR2. Light grey bars and
circles, Crfr2-null; dark grey
bars and circles, Crfr2-null/
Ucn3
+. j Glucose uptake to
peripheral tissues, and (k) total
glycogen and (l) acute incorpo-
ration of glucose into glycogen
in skeletal muscle were in-
creased in Ucn3
+ mice in a GTT
(n=8). m Phosphorylation of
glycogen synthase at Ser641
indicated increased enzyme ac-
tivity (n=7). *p<0.05 vs control
and
†p<0.05 for Crfr2-knockout
vs control;
‡p=0.07 for Ucn3
+
vs control
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+ mice have an
adequate counter-regulatory
response to fasting. a Fasting
insulin downregulation (n=9–
12) in Ucn3
+ mice is appropriate
for blood glucose levels. b De-
crease in liver weight (indicative
of glycogen mobilisation) fol-
lowing fasting (n=6–12) is in-
creased in Ucn3
+ mice. c PAS
staining showed relative deple-
tion of glycogen in the periportal
area of Ucn3
+ livers compared
with controls (×4 magnification
scale bar 500 μm; ×10 magnifi-
cation scale bar 200 μm). d
Pepck mRNA and (e)P E P C K
activity in fed and fasted Ucn3
+
mice (n=6–8). a, b, d, e Black
bars, Ucn3
+; white bars, control.
*p<0.05 for Ucn3
+ vs control
Fig. 4 Ucn3
+ mice do not show increased insulin sensitivity and
are protected against adiposity and hyperglycaemia when on an
HFD. a Insulin:glucose ratios are decreased in fasted Ucn3
+ mice
(black bars and squares) compared with controls (white bars and
squares) (n=10–12). b Change in blood glucose levels during an
ITT in fed mice (n=13–14). c Activating phosphorylation of insulin
signalling intermediates in tissues from fed mice (n=7). d Mean
glucose level and (e) total glucose infused from 70–1 2 0m i ni na
glucose clamp (n=5). f Body weight and (g) energy intake in kJ per
100 g body weight (BW) at 16weeksofage.h Weight loss and (i)b l o o d
glucose levels following fasting, with (j) AUC glucose and (k)b l o o d
glucose levels during a GTT in mice fed LFD or HFD (n=13–17).
*p<0.05 vs control and
†p<0.05 vs LFD. f–k White, control LFD;
black, Ucn3
+ LFD; light grey, control HFD; dark grey, Ucn3
+ HFD
2398 Diabetologia (2011) 54:2392–2403indicating no increase in insulin sensitivity. Total levels of
IRS-1 and Akt did not differ with genotype (not shown).
p70 S6 kinase (p70S6) phosphorylation as a measure of
Akt–mechanistic target of rapamycin (mTOR)–p70S6
signalling pathway activation was not different from
controls under basal conditions (ESM Fig. 2). Finally,
euglycaemic–hyperinsulinaemic clamps demonstrated
increased glucose uptake in Ucn3
+ mice at a fixed insulin
dose (Fig. 4e). However, euglycaemia could not be
achieved even at maximal glucose infusion rates in
Ucn3
+ mice at this standard high physiological insulin
dose (~450 pmol/l [21]), whereas euglycaemia was
achieved in controls (Fig. 4d). This technique relies on
the assumption that non-insulin-dependent glucose uptake
is the same between experimental groups, but our in vivo
data suggest that this was not the case in Ucn3
+ mice.
Hence further comparisons using this standard method for
measuring insulin sensitivity were not attempted.
Ucn3
+ mice resist adiposity and hyperglycaemia on
HFD On control LFD from weaning to 16 weeks, Ucn3
+
mice were heavier than controls, as seen in animals on
normal chow. However, while controls gained weight
despite reducing their energy intake on HFD, Ucn3
+ mice
resisted weight gain while maintaining their energy intake
(Fig. 4f, g). Moreover, LFD-fed Ucn3
+ mice lost a greater
proportion of body weight following fasting, implying
increased mobilisation of energy stores, a process that was
not attenuated by HFD as in controls (Fig. 4h). Ucn3
+ mice
resisted the increase in fat mass on HFD (Table 2). Ucn3
+
mice had lower fasting blood glucose than controls and
resisted HFD-induced hyperglycaemia, showing lower
glucose on both diets (Fig. 4i–k). In an ITT, there was no
significant difference in the initial decrement between
genotypes and therefore again no evidence of increased
insulin sensitivity in Ucn3
+ mice (ESM Fig. 2).
Mechanism for metabolic phenotype and muscular
hypertrophy Ucn2 (the endogenous urocortin in muscle)
and Crfr2 mRNA expression were unchanged in Ucn3
+
skeletal muscle (ESM Fig. 3). To further characterise the
metabolic pathways involved in the phenotype of Ucn3
+
mice, candidate gene expression was examined in skeletal
muscle and liver. AMPK may improve glucose homeostasis
[24], but its activity and mRNA expression were not altered
in Ucn3
+ muscle or liver (Table 3, ESM Fig. 3). Glut1 (also
known as Slc2a1)a n dGlut4 (also known as Slc2a4)
expression was also unchanged in Ucn3
+ mice (Table 3,
ESM Fig. 3). However, Ucp2 and Ucp3 mRNA was
upregulated in muscle (Fig. 5a), suggesting the possibil-
ity of increased metabolic uncoupling or fatty acid
metabolism. Cpt1a mRNA was greatly upregulated in
liver (Fig. 5b), consistent with increased hepatic fat
oxidation. mRNA levels of other metabolic genes were
examined under conditions of HFD and LFD, and when
fed or fasted (Table 3). While these experimental
conditions regulated gene expression as expected, no
effect of genotype was observed.
MyostatinmRNAlevelswereunchangedinUcn3
+ muscle.
However, myostatin propeptide levels were decreased
(Fig. 5c, d). Intriguingly, Igf1 expression was upregulated
~80% in Ucn3
+ skeletal muscle, but unchanged in liver
(Fig. 5e, f). In contrast, serum levels of IGF-1 were only
marginally increased (16%) (Fig. 5g). Circulating growth
hormone levels were unchanged in Ucn3
+ mice (ESM
Fig. 3), thus indicating that CRFR2 may stimulate IGF-1 in
muscle via a paracrine action that causes muscle hypertrophy
and also stimulates glucose uptake independently of the
growth hormone–IGF-1 axis.
Discussion
The model of chronic urocortin 3 overabundance presented
here shows a novel metabolic phenotype, with lean body
composition, increased skeletal muscle mass, increased
disposal and use of glucose in muscle, and increased
energy intake with reduced adiposity on an HFD. Striking-
ly, Ucn3
+ mice have lower blood glucose levels and
Fat pads Control (mg) Ucn3
+ (mg) Control (mg/g BW) Ucn3
+ (mg/g BW)
LFD
Epididymal 734±70 603±50 22.9±2.4 17.0±0.5
a
Mesenteric 363±27 353±15 11.2±0.6 10.0±0.3
a
Inguinal 530±48 438±30 16.5±0.6 12.3±0.6
a
HFD
Epididymal 1,123±99
b 803±106
a 31.0±2.6
b 23.1±2.8
Mesenteric 486±65 320±22
a 13.1±0.9 9.3±0.6
a
Inguinal 909±145
b 482±23
a 24.3±2.5
b 14.0±0.5
a
Table 2 Adiposity of control
and Ucn3
+ mice fed LFD or
HFD
Data are mean±SEM, n=6–9
ap<0.05 vs control;
bp<0.05 vs LFD
BW, body weight
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Crfr2-, Ucn2- and Ucn3-knockout models do not exhibit
until challenged with HFD or aged. Interestingly, Ucn3
+
mice do not show increased insulin sensitivity, suggesting
that augmented glucose uptake occurs largely independent-
ly of insulin action. This again contrasts with the knockout
mice, all of which exhibit increased insulin sensitivity,
albeit via different mechanisms [9–11, 14]. Accordingly,
the metabolic alterations in Ucn3
+ mice appear to be
primarily in carbohydrate metabolism, with accelerated
glucose uptake and metabolism by muscle, and increased
RER reflecting greater proportional carbohydrate use [25].
An AMPK-dependent role for CRFR2 in stimulating
thermogenesis in skeletal muscle has been described [13],
suggesting a possible mechanism by which glucose uptake
to muscle may be enhanced in Ucn3
+ mice. However, we
did not find evidence for increased AMPK activity, but did
observe upregulation of uncoupling proteins (UCP) 2 and 3.
These mitochondrial proteins are normally produced in
skeletal muscle, where their physiological functions are
highly controversial [26, 27]. UCP3 has been proposed to
facilitate fatty acid translocation and oxidation, and to
mitigate reactive oxygen species production. Its primary
role is not generally considered to be thermogenesis, but it
does have the capacity to stimulate heat production and
glucose oxidation in vivo, all roles compatible with the
phenotype of Ucn3
+ mice. UCP2 is even less well
understood, but is generally proposed to fulfil similar
functions. Increased UCP activity, as observed in transgenic
mice, will result in increased mitochondrial oxidative
phosphorylation and glucose metabolism and thus uptake,
as well as increased fatty acid metabolism [28, 29].
Conversely, enhanced glucose transport achieved by over-
abundance of GLUT4 results in increased UCP production
and activity in skeletal muscle, which in turn raises glucose
use and lowers blood glucose [30]. This is plausibly the
effective mechanism in Ucn3
+ mice, with the increase in
glucose metabolism responsible for protection against the
diet-induced obesity seen in control mice.
Transgenic mouse models of increased UCP gene
expression or increased metabolic rate normally exhibit
decreased body weight due to lean body composition,
Fig. 5 a Ucp2 andUcp3 mRNA in muscle (n=11–15). b Cpt1a mRNA
in liver (n=6–8). c Quantification of myostatin protein levels in (d)
western blot (C, control; U3, Ucn3
+)( n=11). e Igf1 mRNA (n=11–15),
and (f) IGF-1 protein in muscle and (g) IGF-1 plasma levels (n=11).
mRNA levels (a, b, e) are expressed as percentage of the average value
of all samples. *p<0.05 vs control and
†p< 0 . 0 5v sf e d .W h i t e ,c o n t r o l
fed; black, Ucn3
+ fed; light grey, control fasted; dark grey, Ucn3
+ fasted
Table 3 Genes not altered in Ucn3
+ mice compared with controls
mRNA Tissue Function
Glut4 Muscle Glucose transport
Hk2 Muscle Glucose transport
Pdha1 Muscle Glycolysis/TCA cycle
Cs Muscle TCA cycle
Prkaa2 Muscle Fat and glucose catabolism
Cpt1b Muscle Lipid oxidation
Acsl1 Muscle Fatty acid metabolism
Lpl Muscle Fatty acid metabolism
Ppargc1a Muscle Mitochondrial metabolism
Fasn Muscle, liver Lipogenesis
Ppara Muscle, liver Control of fat oxidation
Ppard Muscle, liver Control of fat oxidation
Srebf1 Liver Lipogenesis
Gpam Liver Esterification
Acaca Liver Substrate switching
Pdk4 Liver Substrate switching
G6pc3 Liver Gluconeogenesis
Ucp1 BAT, WAT Mitochondrial uncoupling
BAT, brown adipose tissue; TCA, tricarboxylic acid; WAT, white
adipose tissue
2400 Diabetologia (2011) 54:2392–2403whereas a notable feature of Ucn3
+ mice is their increased
body weight, entirely due to increased muscle mass. This
muscular hypertrophy helps explain their metabolic pheno-
type. Increased IGF-1 abundance in Ucn3
+ skeletal muscle
provides a plausible link between the muscular and
metabolic phenotypes of the mice. Decreased myostatin
expression may also contribute to muscle hypertrophy;
indeed, myostatin-null mice show similar fasting glucose
and body composition responses to HFD as do Ucn3
+ mice
[31]. However, myostatin is quantitatively much less
affected than IGF-1 in Ucn3
+ mice.
In addition to its anabolic effects, IGF-1 has long been
known to exert metabolic effects similar to insulin, with
increased glucose uptake and glycogen synthesis, and
hypoglycaemia as seen in Ucn3
+ mice [32, 33]. These
effects are mediated via the IGF-1 receptor in skeletal
muscle [34]. Overabundance of IGF-1 in muscle can cause
a shift towards glycolytic metabolism [35], which may
improve body composition and insulin sensitivity [36].
Thus IGF-1 may be responsible for the observed shift
towards type 2 muscle fibres in Ucn3
+ mice. Transgenic or
pharmacological models of increased IGF-1 levels show
evidence of increased flux through various signalling
pathways including the phosphatidylinositol 3-kinase path-
way in tissues [37, 38], whereas decreased IRS-1 and Akt
phosphorylation was seen in tissues from Ucn3
+ mice
following fasting. This may be because the observed
increase in IGF-1 production, and hence presumably action,
is of a lesser magnitude to that seen in these other models,
a n dt h eI G F - 1a x i si nUcn3
+ mice will still be subject to
regulation by endogenous factors including feeding status.
L i k e w i s e ,n od i f f e r e n c ei nA k t –mTOR–p70S6 protein
synthesis pathway signalling was observed in Ucn3
+ mice
under basal conditions when adaptation of signalling
activity might have been expected. Detailed dynamic
signalling pathway studies under conditions of CRFR2
stimulation should further clarify the role of these
signalling pathways.
While exogenous urocortin 1 administration can
stimulate pituitary growth hormone release [39], the
mechanism by which IGF-1 production is stimulated in
Ucn3
+ mice is more likely to be paracrine. Neither serum
growth hormone nor hepatic IGF-1 levels were increased
in Ucn3
+ mice. It is possible that subtle differences in
growth hormone may have been missed on the single time
point sample due to the pulsatile nature of growth
hormone secretion. However, while growth hormone or
Igf1 transgenic mice show organomegaly and other
aspects of an acromegalic phenotype [40, 41], transgenic
mice overexpressing Igf1 specifically within muscle show
myofibre hypertrophy without systemic features of acro-
megaly [42, 43]. CRFR2 agonists ameliorate muscle
atrophy in a variety of pathological conditions, including
denervation atrophy and cancer cachexia, and will also
increase mass of normal muscles [44–46]. While the
mechanisms underlying this effect have not been described, it
has been shown to be a paracrine effect, strongly suggesting
that urocortin 3 acting locally at CRFR2 is responsible for the
myocyte hypertrophy observed in Ucn3
+ mice. IGF-1
produced within skeletal muscle appears to be released to
the circulation, but this source is a minor contributor in
comparison to liver [47]. The source of the small increase in
serum IGF-1 in Ucn3
+ mice is thus likely to be their
increased muscle content.
Beneficial effects of IGF-1 in type 2 diabetes and other
insulin-resistant states have been observed [37, 48].
Decreased hepatic gluconeogenesis contributes to this;
however, liver contains no IGF-1 receptors and the main
effect of IGF-1 is mediated in skeletal muscle, with effects
on liver metabolism being secondary [49]. Likewise,
evidence for altered hepatic fuel metabolism is seen in
Ucn3
+ mice when CRFR2 has not been demonstrated in
hepatocytes [50]. The Ucn3
+ liver phenotype is apparently
one of increased fatty acid oxidation and gluconeogenesis,
which would seem appropriate compensatory adaptations
for the increased fuel catabolism in muscle tissue. The
Crfr2-knockout phenotype has been ascribed to increased
sympathetic drive from the central nervous system upregu-
lating brown adipose tissue UCP1 [10]. However, this does
not seem to be occurring in Ucn3
+ mice. Nevertheless,
altered sympathetic drive to splanchnic organs including
liver cannot be entirely ruled out as contributing in part to
their phenotype.
Overall, Ucn3
+ mice demonstrate that CRFR2 can drive
skeletal muscle hypertrophy and glucose uptake even in the
face of dietary challenge. CRFR2 agonists may be useful
therapies to maintain muscle mass and bypass the muscle
insulin resistance that so commonly occurs, most notably
with ageing.
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